Clin Osteol 2014; 19(4): 93-96

Effect of breast cancer therapy on bone mineral densityOriginal contributions

A. Skladaná

In 75 % to 80 % of breast cancer cases, estrogen or progesterone hormone receptors are present, with tumor growth progression influ­ enced by estrogens and regression influenced by ovariectomy, receptor blockers, chemotherapy (inducing primary ovarian failure in premenopausal women) and antihormone therapy with drugs (aromatase inhibitors, LHRH agonists). The above procedures have a potential to decrease bone mineral density, primarily by disrupting the estrogen-osteoblast-bone resorption inhibition axis. Lower estrogen production increases the activity of osteoclasts. Current recommendations for preventing bone mineral density decrease in breast cancer therapy include adequate calcium and vitamin D intake, take and, in osteoporotic patients, bisphosphonate therapy.

Keywords: breast cancer, estrogens, hormone therapy, bone resorption

Published: December 11, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Skladaná A. Effect of breast cancer therapy on bone mineral density. Osteologický bulletin. 2014;19(4):93-96.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Abrahámová J. Adjuvantní hormonální léčba č nopauzálních žen. Onkologická péče 2008;2:6-7.
    2. Hirbe A, Morgn EA, Ulackan O, Weilbaecher K. Sk cancer therapies. J Clin Cancer res 2006; 12:6309. Go to original source...
    3. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G et al. Zolendronic acid pre cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007;25:820. Go to original source...
    4. Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rap Oncol 2001;19:3306. Go to original source...
    5. Saarto T, Blomqvist C, Valimaki M et al. Chemical castration induced by ad cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopuasal breast cancer patients. J Clin Oncol 1997;15:1341. Go to original source...
    6. McCloskey E. Effects of third-generation aromatase inhibitors on bone. Eur J Cancer 2006;42:1044. Go to original source...
    7. Perez EA Safety of aromatase inhibitors in the adjuvant setting. Breast Ca treat 2007;105 Suppl 1:75.
    8. Eastell R. Aromatase inhibitors and bone. J Steroid Biochem Mol Biol 2007; 106:157. Go to original source...
    9. Saad F, Adachi JD, Brown JP, et al. Cancer treatment-induced bone loss in bre and prostate cancer. J Clin Oncol 2008;26:5465. Go to original source...
    10. Eastell R, Adams JE, Coleman RE et al. Effect of anastrozole on bone mineral denzity 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 2008;26:1051. Go to original source...
    11. Warming L, Hassager C, Christiansen C. Changes in bone mineral density with age in men and women: a longitudinal study. Osteoporosis Int 2002;13:105. Go to original source...
    12. Ramaswamy B, Shapiro C. Osteopenia and osteoporosis in women in breast can­ cer. Semin oncol 2003;763-775. Go to original source...
    13. Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause du­ ring the first year after breast cancer diagnosis. J Clin Oncol 1999;17:236 Go to original source...
    14. Bines J, Oleske DM, Cobleigh MA Ovarian function in premenopausal women treated with ajuvant chemotherapy for breast cancer. J Clin Oncol 1996;14: 1718-1729. Go to original source...
    15. Lester J, Dodwell D, McCloskey E, Coleman R. The causes and treatment of bone loss associated with carcinoma of the breast. Cancer Treat Rev 2005;31:115-142. Go to original source...
    16. Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 2001;19:3306-3311. Go to original source...
    17. Hughes DE, Dai A, Tiffee JC, Li HH, Mundy GR, Boyce BF. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-B. Nat Med 1996;2:1132-1136. Go to original source...
    18. Kameda T, Mano H, Yuasa T et al. Estrogen inhibits bone resorption by inducing apoptosis of the bone-resorbing osteoclasts. J Exp Med 1997;186: 489495. Go to original source...
    19. Saad F, Olsson C, Schulman CC. Skeletal morbidity in men with prostate canc quality of life considerations trough the continuum of care. Eur Urol 2004;46: 731-739; discission 739-740. Go to original source...
    20. Cosman F. Selective estrogen receptor modulators. Clin Geriatr Med 2003;19: 371-379. Go to original source...
    21. Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on b mineral density measured by dual-energy x-ray absorptiometry in healthy preme­ nopausal and postmenopausal women. J Clin Oncol 1996;14:78-84. Go to original source...
    22. Goldhirsch A, Wood WC,Coates AS et al. Strategies for subtypes-dealing wit diversity of breast cancer: highlights of the St. Gallen International Expert. Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011;22:1736-1747. Go to original source...
    23. Dowsett M, Cuzick J, Ingle J et al. Meta-analysis of breast cancer outcom juvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010;28: 509- 518. Go to original source...
    24. Confavreux CB, Fontana A, Guastalla JP et al. Estrogen-dependent increas ne turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. Bone 2007;41:346. Go to original source...
    25. Simpson ER, Dowsett M. Aromatase and its inhibitors: significance for breast c cer therapy. Recent Prog Horm Res 2002;57:317-338. Go to original source...
    26. Kanis JA, Melton LJ, Christiansen C 3rd et al. The diagnosis of osteoporosis. J Bone Miner Res 1994;9:1137-1141. Go to original source...
    27. Eastell R, Hannon RA, Cuzick J et al. Effect of an aromatase inhibitor on BMD and bone turnover markers 2-year results of the Anastrozole,Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 2006;21:1215-1223. Go to original source...
    28. Shapiro CL, Manola J, Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 2001;19:3306-3311. Go to original source...
    29. Coleman RE, Banks LM, Girgis SI et al. Skeletal effects of exemestane on bone­ mineral density, bone biomarkers and fracture incidence in postmenopausal wo­ men with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 2007;8:119-127. Go to original source...
    30. Goss PE, Ingle JN, Martino S et al. Randomized trial of letrozole following moxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA17. J Natl Cancer Inst 2005;97:1262-1271. Go to original source...
    31. Eastell R, Adams JE, Coleman RE et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 2008;26:1051-1057. Go to original source...
    32. Tang SC. Women and bone health: maximizing the benefits of aromatase inhibi­ tor therapy. Oncology 2010;79:13-26. Go to original source...
    33. Rabaglio M, Sun Z, Price KN et al. Bone fractures among postmenopausal pa­ tients with endocrine-responsive early breast cancer treated with 5 years of le zole or tamoxifen in the BIG 1-98 trial. Ann Oncol 2009;20:1489-1498. Go to original source...
    34. Bischoff-Ferrari HA, Shao A, Dawson-Hughes B et al. Benefit-risk assessment of vitamin D supplementation. Osteoporos Int 2010;21:1121-1132. Go to original source...
    35. Peterlík M, Grant WB, Cross HS et al. Calcium, vitamin D and ca res 2007;29:3687-3698.
    36. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-281. Go to original source...
    37. Adami S, Giannini S, Bianchi G et al. Vitamin D status and response to treatm in post-menopausal osteoporosis. Osteoporos Int 2009;20:239-244. Go to original source...
    38. Tuohimaa P, Tenkanen L, Ahonen M et al. Both high and low levels of blood vi­ tamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic contries. Int J Cancer 2004;108:104-108. Go to original source...
    39. Holick MF, Binkley NC, Bischoff-Ferrari HA et al. Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2011. Go to original source...
    40. Rusell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bis­ phosphonates similarities and differe efficacy. Osteoporos Int 2008;19:733. Go to original source...
    41. Hillner B, Inge J, Berenson J et al. American Society of Clinical Oncology update on the role of bisphosphonates and bone health issues in breast cancer. J Clin Oncol 2003;21:4042^057. Go to original source...
    42. Hadji P, Aapro MS, Body JJ et al. Management of aromatase inhibitor-asso bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann Oncol 2011. Go to original source...
    43. Hadji P, Body JJ, Aapro MS et al. Practical guidance for the ma matase inhibitor-associated bone loss. Ann Oncol 2008;19:1407-1416. Go to original source...
    44. Reid DM, Doughty J, Eastell R et al. Guidance for the management of breas cer treatment-induced bone loss: a consensus position from a UK Expert Group. Cancer Treat Rev 2008;34:S3-S18. Go to original source...
    45. Ferlay J, Shin HR, Bray F et al. Estimates GLOBOCAN 2008. Int J Cancer 2010;127:2893-2917. Go to original source...
    46. Smith MR. Osteoporosis during an Urology 2002;60:79-85, discusion 86. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.